查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1586172

细胞和基因疗法市场：按产品、递送方法、应用和最终用户 - 2025-2030 年全球预测

Cell & Gene Therapy Market by Product (Cell Therapy, Gene Therapy), Delivery Method (Ex Vivo, In Vivo), Application, End-User - Global Forecast 2025-2030
出版日期: | 出版商: 360iResearch | 英文 194 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

细胞和基因治疗市场2023年估值为277亿美元，预计2024年将达到346.3亿美元，复合年增长率为25.39%，预计到2030年将达到1350.4亿美元。

细胞和基因疗法（CGT）涉及使用生物疗法将遗传物质引入患者的细胞中以治疗或预防疾病。这一发展中的领域对于解决未满足的医疗需求至关重要，特别是在罕见遗传疾病、癌症和某些慢性病方面。增加对基因组研究、先进临床试验的投资以及加快监管途径（例如 FDA 的再生医学先进疗法指定）是成长的催化剂。应用范围从肿瘤学（其中 CAR-T 等治疗方法已显示出令人印象深刻的缓解率）到再生医学（治疗神经系统和心血管疾病）。潜在的最终用途扩展到医院、癌症治疗中心和专科诊所。由于 CRISPR 技术的进步、个人化医疗方法以及慢性病盛行率的增加，该市场正在经历显着成长。扩大 CGT 涵盖的适应症、建立强大的製造能力以及与生物製药公司合作以增强治疗特异性和递送机制方面存在机会。然而，挑战依然存在，包括高昂的开发和处理成本、复杂的製造流程以及严格的监管要求。此外，对基因改造和潜在长期影响的伦理担忧也构成了障碍。为了促进创新，现成的同种异体疗法、用于高效基因传递的增强载体设计以及人工智慧主导的标靶治疗药物发现等研究可能会带来重大进展。此外，可以透过策略性定价模型和彻底的公私合营关係来增强患者的可及性，从而解决市场障碍。目前，市场成长充满活力，受到快速技术进步和不断上升的核准率的推动，但受到生产可扩展性问题和报销状态波动的限制。克服交付挑战、优化製造流程以及优先考虑以患者为中心的模型对于利用细胞和基因治疗领域快速成长的机会至关重要。

主要市场统计
基准年[2023] 277亿美元
预测年份 [2024] 346.3亿美元
预测年份 [2030] 1350.4亿美元
复合年增长率（%） 25.39%

市场动态：针对快速发展的细胞和基因治疗市场揭示的关键市场见解

供需的动态交互作用正在改变细胞和基因治疗市场。透过了解这些不断变化的市场动态，公司可以准备好做出明智的投资决策、完善策略决策并抓住新的商机。全面了解这些趋势可以帮助企业降低政治、地理、技术、社会和经济领域的风险，同时消费行为及其对製造成本的影响以及对采购趋势的影响。

  • 市场驱动因素
    • 慢性病盛行率上升和基因治疗的重要性
    • 随着医疗保健支出的增加，人们对基因和细胞疗法的认识也不断增强
    • 临床试验数量大幅增加，政府审批数量增加
  • 市场限制因素
    • 与基因和细胞治疗相关的高成本
  • 市场机会
    • 细胞和基因发育中先进分析技术的出现
    • 增加製药和生物製药研究的投资
  • 市场挑战
    • 细胞/基因治疗的报销政策不完善

波特的五力：驾驭细胞与基因治疗市场的策略工具

波特的五力框架是理解市场竞争格局的重要工具。波特的五力框架为评估公司的竞争地位和探索策略机会提供了清晰的方法。该框架可帮助公司评估市场动态并确定新业务的盈利。这些见解使公司能够利用自己的优势，解决弱点并避免潜在的挑战，从而确保更强大的市场地位。

PESTLE分析：了解细胞和基因治疗市场的外部影响

外部宏观环境因素在塑造细胞和基因治疗市场的绩效动态方面发挥着至关重要的作用。对政治、经济、社会、技术、法律和环境因素的分析提供了应对这些影响所需的资讯。透过调查 PESTLE 因素，公司可以更了解潜在的风险和机会。这种分析可以帮助公司预测法规、消费者偏好和经济趋势的变化，并为他们做出积极主动的决策做好准备。

市场占有率分析 了解细胞和基因治疗市场的竞争状况

细胞和基因治疗市场的详细市场占有率分析提供了对供应商绩效的全面评估。公司可以透过比较收益、客户群和成长率等关键指标来揭示其竞争地位。该分析揭示了市场集中、分散和整合的趋势，为供应商提供了製定策略决策所需的洞察力，以应对日益激烈的竞争。

FPNV定位矩阵细胞与基因治疗市场供应商绩效评估

FPNV定位矩阵是评估细胞和基因疗法市场供应商的重要工具。此矩阵允许业务组织根据商务策略和产品满意度评估供应商，从而做出与其目标相符的明智决策。这四个象限使您能够清晰、准确地划分供应商，以确定最能满足您的策略目标的合作伙伴和解决方案。

策略分析和建议绘製细胞和基因治疗市场的成功之路

细胞和基因治疗市场的策略分析对于旨在加强其在全球市场的影响力的公司至关重要。透过审查关键资源、能力和绩效指标，公司可以识别成长机会并努力改进。这种方法使您能够克服竞争环境中的挑战，利用新的商机，并取得长期成功。

本报告对市场进行了全面分析，涵盖关键重点领域：

1. 市场渗透率：详细检视当前市场环境、主要企业的广泛资料、评估其在市场中的影响力和整体影响力。

2. 市场开拓：辨识新兴市场的成长机会，评估现有领域的扩张潜力，并提供未来成长的策略蓝图。

3. 市场多元化：分析近期产品发布、开拓地区、关键产业进展、塑造市场的策略投资。

4. 竞争评估与情报：彻底分析竞争格局，检验市场占有率、业务策略、产品系列、认证、监理核准、专利趋势、主要企业的技术进步等。

5. 产品开发与创新：重点在于有望推动未来市场成长的最尖端科技、研发活动和产品创新。

我们也回答重要问题，帮助相关人员做出明智的决策：

1.目前的市场规模和未来的成长预测是多少？

2. 哪些产品、区隔市场和地区提供最佳投资机会？

3.塑造市场的主要技术趋势和监管影响是什么？

4.主要厂商的市场占有率和竞争地位如何？

5. 推动供应商市场进入和退出策略的收益来源和策略机会是什么？

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病的增加和基因治疗的重要性
      • 人们对基因和细胞疗法的认识不断增强，医疗保健成本不断上升
      • 临床试验数量大幅增加，政府核准数量增加
    • 抑制因素
      • 与基因和细胞治疗相关的高成本
    • 机会
      • 细胞和基因开发中先进分析技术的出现
      • 增加製药和生物製药研究的投资
    • 任务
      • 报销政策不适用于细胞和基因治疗
  • 市场区隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 经济
    • 社群
    • 技术的
    • 合法地
    • 环境

第六章细胞/基因治疗市场：副产品

  • 细胞疗法
  • 基因治疗

第七章以递送方式分類的细胞和基因治疗市场

  • 体外
  • In vivo

第八章细胞/基因治疗市场：依应用分类

  • 皮肤科
  • 肌肉骨骼
  • 肿瘤学

第九章细胞/基因治疗市场：依最终用户分类

  • 门诊手术中心
  • 癌症护理中心
  • 医院
  • 创伤护理中心

第十章美洲细胞与基因治疗市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太细胞与基因治疗市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章欧洲、中东和非洲的细胞和基因治疗市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
  • 战略分析和建议

公司名单

  • Abeona Therapeutics Inc.
  • Adaptimmune Limited
  • AGC Biologics
  • Alnylam Pharmaceuticals, Inc.
  • American Gene Technologies Inc.
  • Amgen Inc.
  • AnGes, Inc.
  • Astellas Gene Therapies
  • Beacon Therapeutics Limited
  • Biogen Inc.
  • bluebird bio, Inc.
  • Cellectis SA
  • Editas Medicine, Inc.
  • F. Hoffmann-La Roche Ltd
  • Immuneel Therapeutics Private Limited
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Mustang Bio, Inc.
  • Novartis AG
  • Orchard Therapeutics PLC
  • Poseida Therapeutics, Inc.
  • Sangamo Therapeutics, Inc.
  • Sarepta Therapeutics, Inc.
  • Sibiono GeneTech Co. Ltd.
  • Uniqure NV
Product Code: MRR-450A0628CE5A

The Cell & Gene Therapy Market was valued at USD 27.70 billion in 2023, expected to reach USD 34.63 billion in 2024, and is projected to grow at a CAGR of 25.39%, to USD 135.04 billion by 2030.

Cell and gene therapy (CGT) encompasses the use of biological treatments that modify or introduce genetic material into a patient's cells to treat or prevent disease. This evolving sector is notably vital for addressing unmet medical needs, especially for rare genetic disorders, cancers, and certain chronic conditions. Increasing investments in genomic research, advanced clinical trials, and the acceleration through expedited regulatory pathways like the FDA's regenerative medicine advanced therapy designation have catalyzed growth. Applications span from oncology, where therapies like CAR-T have shown remarkable remission rates, to regenerative medicine treating neurological disorders and cardiovascular diseases. The end-use potential extends to hospitals, cancer treatment centers, and specialized clinics. The market is experiencing significant growth driven by advances in CRISPR technology, personalized medicine approaches, and an increasing prevalence of chronic diseases. Opportunities lie in expanding the indications covered by CGT, establishing robust manufacturing capabilities, and biopharma collaborations to enhance therapy specificity and delivery mechanisms. However, challenges remain, including high development and therapy costs, complex manufacturing processes, and strict regulatory requirements. Additionally, ethical concerns over genetic modifications and potential long-term impacts pose hurdles. To foster innovation, research into off-the-shelf allogeneic therapies, enhanced vector designs for efficient gene delivery, and AI-driven drug discovery for targeted therapies can provide significant advancements. Furthermore, enhancing patient access through strategic pricing models and in-depth public-private partnerships can address market barriers. Market growth is currently dynamic, spurred by rapid technological advancements and growing approval rates, yet tempered by production scalability issues and variable reimbursement landscapes. Moving forward, a focus on overcoming delivery challenges, optimizing manufacturing processes, and prioritizing patient-centric models will be pivotal in capitalizing on the burgeoning opportunities of the cell and gene therapy sector.

KEY MARKET STATISTICS
Base Year [2023] USD 27.70 billion
Estimated Year [2024] USD 34.63 billion
Forecast Year [2030] USD 135.04 billion
CAGR (%) 25.39%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Cell & Gene Therapy Market

The Cell & Gene Therapy Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Rising prevalence of chronic diseases and significance for gene therapy treatment
    • Growing awareness of gene & cell therapies coupled with increase in healthcare expenditure
    • Significant growth in numbers of clinical trials and increasing governmental approvals
  • Market Restraints
    • High costs asscoiated with the gene and cell therapy treatment
  • Market Opportunities
    • Emergence of advanced analytical technologies in development of cell & gene
    • Rising investments in pharmaceutical and biopharmaceutical research
  • Market Challenges
    • Unavailability of reimbursement policies for cell & gene therapies

Porter's Five Forces: A Strategic Tool for Navigating the Cell & Gene Therapy Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Cell & Gene Therapy Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Cell & Gene Therapy Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Cell & Gene Therapy Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Cell & Gene Therapy Market

A detailed market share analysis in the Cell & Gene Therapy Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Cell & Gene Therapy Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Cell & Gene Therapy Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Cell & Gene Therapy Market

A strategic analysis of the Cell & Gene Therapy Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Cell & Gene Therapy Market, highlighting leading vendors and their innovative profiles. These include Abeona Therapeutics Inc., Adaptimmune Limited, AGC Biologics, Alnylam Pharmaceuticals, Inc., American Gene Technologies Inc., Amgen Inc., AnGes, Inc., Astellas Gene Therapies, Beacon Therapeutics Limited, Biogen Inc., bluebird bio, Inc., Cellectis SA, Editas Medicine, Inc., F. Hoffmann-La Roche Ltd, Immuneel Therapeutics Private Limited, Ionis Pharmaceuticals, Inc., Merck KGaA, Mustang Bio, Inc., Novartis AG, Orchard Therapeutics PLC, Poseida Therapeutics, Inc., Sangamo Therapeutics, Inc., Sarepta Therapeutics, Inc., Sibiono GeneTech Co. Ltd., and Uniqure N.V..

Market Segmentation & Coverage

This research report categorizes the Cell & Gene Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Product, market is studied across Cell Therapy and Gene Therapy.
  • Based on Delivery Method, market is studied across Ex Vivo and In Vivo.
  • Based on Application, market is studied across Dermatology, Musculoskeletal, and Oncology.
  • Based on End-User, market is studied across Ambulatory Surgical Centers, Cancer Care Centers, Hospitals, and Wound Care Centers.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Rising prevalence of chronic diseases and significance for gene therapy treatment
      • 5.1.1.2. Growing awareness of gene & cell therapies coupled with increase in healthcare expenditure
      • 5.1.1.3. Significant growth in numbers of clinical trials and increasing governmental approvals
    • 5.1.2. Restraints
      • 5.1.2.1. High costs asscoiated with the gene and cell therapy treatment
    • 5.1.3. Opportunities
      • 5.1.3.1. Emergence of advanced analytical technologies in development of cell & gene
      • 5.1.3.2. Rising investments in pharmaceutical and biopharmaceutical research
    • 5.1.4. Challenges
      • 5.1.4.1. Unavailability of reimbursement policies for cell & gene therapies
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. Cell & Gene Therapy Market, by Product

  • 6.1. Introduction
  • 6.2. Cell Therapy
  • 6.3. Gene Therapy

7. Cell & Gene Therapy Market, by Delivery Method

  • 7.1. Introduction
  • 7.2. Ex Vivo
  • 7.3. In Vivo

8. Cell & Gene Therapy Market, by Application

  • 8.1. Introduction
  • 8.2. Dermatology
  • 8.3. Musculoskeletal
  • 8.4. Oncology

9. Cell & Gene Therapy Market, by End-User

  • 9.1. Introduction
  • 9.2. Ambulatory Surgical Centers
  • 9.3. Cancer Care Centers
  • 9.4. Hospitals
  • 9.5. Wound Care Centers

10. Americas Cell & Gene Therapy Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Cell & Gene Therapy Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Cell & Gene Therapy Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
  • 13.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. Abeona Therapeutics Inc.
  • 2. Adaptimmune Limited
  • 3. AGC Biologics
  • 4. Alnylam Pharmaceuticals, Inc.
  • 5. American Gene Technologies Inc.
  • 6. Amgen Inc.
  • 7. AnGes, Inc.
  • 8. Astellas Gene Therapies
  • 9. Beacon Therapeutics Limited
  • 10. Biogen Inc.
  • 11. bluebird bio, Inc.
  • 12. Cellectis SA
  • 13. Editas Medicine, Inc.
  • 14. F. Hoffmann-La Roche Ltd
  • 15. Immuneel Therapeutics Private Limited
  • 16. Ionis Pharmaceuticals, Inc.
  • 17. Merck KGaA
  • 18. Mustang Bio, Inc.
  • 19. Novartis AG
  • 20. Orchard Therapeutics PLC
  • 21. Poseida Therapeutics, Inc.
  • 22. Sangamo Therapeutics, Inc.
  • 23. Sarepta Therapeutics, Inc.
  • 24. Sibiono GeneTech Co. Ltd.
  • 25. Uniqure N.V.

LIST OF FIGURES

  • FIGURE 1. CELL & GENE THERAPY MARKET RESEARCH PROCESS
  • FIGURE 2. CELL & GENE THERAPY MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 15. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 17. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. CELL & GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 23. CELL & GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. CELL & GENE THERAPY MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL CELL & GENE THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. CELL & GENE THERAPY MARKET DYNAMICS
  • TABLE 7. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CELL THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY GENE THERAPY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY EX VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY IN VIVO, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY DERMATOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY MUSCULOSKELETAL, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY AMBULATORY SURGICAL CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY CANCER CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL CELL & GENE THERAPY MARKET SIZE, BY WOUND CARE CENTERS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 23. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 24. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 25. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 26. AMERICAS CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 27. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 28. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 29. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 30. ARGENTINA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 31. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 33. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 34. BRAZIL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 35. CANADA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. CANADA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 37. CANADA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 38. CANADA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 39. MEXICO CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. MEXICO CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 41. MEXICO CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 42. MEXICO CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 43. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 45. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. UNITED STATES CELL & GENE THERAPY MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 48. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 49. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 50. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 51. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 52. ASIA-PACIFIC CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 53. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 55. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 56. AUSTRALIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 57. CHINA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 58. CHINA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 59. CHINA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 60. CHINA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 61. INDIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 62. INDIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 63. INDIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. INDIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 66. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 67. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 68. INDONESIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 69. JAPAN CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 70. JAPAN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 71. JAPAN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 72. JAPAN CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 73. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 74. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 75. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 76. MALAYSIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 77. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 78. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 79. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 80. PHILIPPINES CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 81. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 82. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 83. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. SINGAPORE CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 87. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 88. SOUTH KOREA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 89. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 90. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 91. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 92. TAIWAN CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 93. THAILAND CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 94. THAILAND CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 95. THAILAND CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. THAILAND CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 98. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 99. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 100. VIETNAM CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 101. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 102. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 103. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 104. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 105. EUROPE, MIDDLE EAST & AFRICA CELL & GENE THERAPY MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 106. DENMARK CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 107. DENMARK CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 108. DENMARK CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 109. DENMARK CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 110. EGYPT CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 111. EGYPT CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 112. EGYPT CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 113. EGYPT CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 114. FINLAND CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 115. FINLAND CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 116. FINLAND CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 117. FINLAND CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 118. FRANCE CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 119. FRANCE CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 120. FRANCE CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 121. FRANCE CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 122. GERMANY CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 123. GERMANY CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 124. GERMANY CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 125. GERMANY CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 126. ISRAEL CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 127. ISRAEL CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 128. ISRAEL CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 129. ISRAEL CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 130. ITALY CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 131. ITALY CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 132. ITALY CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 133. ITALY CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 134. NETHERLANDS CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 135. NETHERLANDS CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 136. NETHERLANDS CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 137. NETHERLANDS CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 138. NIGERIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 139. NIGERIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 140. NIGERIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 141. NIGERIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 142. NORWAY CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 143. NORWAY CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 144. NORWAY CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 145. NORWAY CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 146. POLAND CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 147. POLAND CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 148. POLAND CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 149. POLAND CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 150. QATAR CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 151. QATAR CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 152. QATAR CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 153. QATAR CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 154. RUSSIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 155. RUSSIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 156. RUSSIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 157. RUSSIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 158. SAUDI ARABIA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 159. SAUDI ARABIA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 160. SAUDI ARABIA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 161. SAUDI ARABIA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 162. SOUTH AFRICA CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 163. SOUTH AFRICA CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 164. SOUTH AFRICA CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 165. SOUTH AFRICA CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 166. SPAIN CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 167. SPAIN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 168. SPAIN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. SPAIN CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. SWEDEN CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 171. SWEDEN CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 172. SWEDEN CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 173. SWEDEN CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 174. SWITZERLAND CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 175. SWITZERLAND CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 176. SWITZERLAND CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 177. SWITZERLAND CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 178. TURKEY CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 179. TURKEY CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 180. TURKEY CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. TURKEY CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. UNITED ARAB EMIRATES CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 183. UNITED ARAB EMIRATES CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 184. UNITED ARAB EMIRATES CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 185. UNITED ARAB EMIRATES CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 186. UNITED KINGDOM CELL & GENE THERAPY MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 187. UNITED KINGDOM CELL & GENE THERAPY MARKET SIZE, BY DELIVERY METHOD, 2018-2030 (USD MILLION)
  • TABLE 188. UNITED KINGDOM CELL & GENE THERAPY MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 189. UNITED KINGDOM CELL & GENE THERAPY MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 190. CELL & GENE THERAPY MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 191. CELL & GENE THERAPY MARKET, FPNV POSITIONING MATRIX, 2023